335 related articles for article (PubMed ID: 36400418)
21. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
22. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
[TBL] [Abstract][Full Text] [Related]
23. Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Xie Y; Hu Y; Zhu Y; Wang H; Wang QZ; Li YQ; Wang JB; Zhang ZY; Zhang DK; Liu XW; Lu NH
Helicobacter; 2023 Jun; 28(3):e12978. PubMed ID: 37002653
[TBL] [Abstract][Full Text] [Related]
24. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
25. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
26. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
[TBL] [Abstract][Full Text] [Related]
27. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
28. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
30. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
Huang TH; Yang SC; Tai WC; Liang CM; Kuo CM; Yao CC; Wu CK; Kuo YH; Chou YP; Lee CH; Wu KL; Chuah SK
Biomed J; 2021 Dec; 44(6 Suppl 2):S275-S281. PubMed ID: 35292265
[TBL] [Abstract][Full Text] [Related]
31. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
32. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
34. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Demir M; Göktürk S; Oztürk NA; Serin E; Yilmaz U
Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
[TBL] [Abstract][Full Text] [Related]
35. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
Yang J; Zhang Y; Fan L; Zhu YJ; Wang TY; Wang XW; Chen DF; Lan CH
Am J Gastroenterol; 2019 Mar; 114(3):437-445. PubMed ID: 30807294
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Tang D; Yuan L; Yue C; Cai T; Yao Y; Wang F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):772-778. PubMed ID: 30124214
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
38. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
39. [Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori].
Guo T; Wang Q; Wu X; Li XQ; Li Y; Fei GJ; Shu HJ; Li JN; Qian JM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Feb; 41(1):75-79. PubMed ID: 30837046
[TBL] [Abstract][Full Text] [Related]
40. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]